Ilaris

Canakinumab, the active ingredient in Ilaris, is a monoclonal antibody presented as a 150 mg/1 mL solution for injection for subcutaneous use. It selectively neutralizes interleukin‑1β and is approved for cryopyrin‑associated periodic syndromes—including familial cold autoinflammatory syndrome, Muckle‑Wells syndrome and neonatal‑onset multisystem inflammatory disease—along with systemic juvenile idiopathic arthritis, adult‑onset Still’s disease, and acute gout flares.

GNH USA supplies Ilaris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics, including specialty centers and research institutions worldwide and ensures compliance with local regulatory requirements.

Canakinumab (Ilaris) is an interleukin‑1β inhibitor used to manage autoinflammatory and inflammatory disorders.

- Cryopyrin‑associated periodic syndromes (CAPS): reduces frequency and severity of inflammatory episodes. - Systemic juvenile idiopathic arthritis (SJIA): controls systemic inflammation and joint symptoms. - Adult‑onset Still’s disease: alleviates fever, rash and arthritis. - Gout flares: provides rapid relief of acute gouty arthritis. - Atherosclerotic disease (investigational): studied for reducing cardiovascular events.

Canakinumab may be associated with a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site reactions: redness, swelling or pain at the injection site. - Upper respiratory tract infection: mild cold‑like symptoms. - Headache: transient headache episodes. - Diarrhea: loose stools, usually self‑limiting. - Nausea: occasional feeling of nausea. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Serious infections: increased risk of bacterial, viral or fungal infections. - Neutropenia: low neutrophil count requiring monitoring. - Hypersensitivity reactions: rash, urticaria or anaphylaxis. - Gastrointestinal perforation: rare but severe abdominal events. - Elevated liver enzymes: potential hepatic involvement. - Malignancy (rare): isolated reports of cancer development.

When prescribing canakinumab, clinicians should consider several precautionary measures to minimize risk.

- Screening for active infections: assess before initiating therapy. - Monitoring blood counts: perform regular CBC to detect neutropenia. - Evaluating liver function: check transaminases periodically. - Vaccination status: avoid live vaccines during treatment. - Pregnancy and lactation: use only if benefit outweighs risk (category unknown). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Canakinumab can interact with other agents, primarily affecting immune function or drug clearance.

Major Interactions (Avoid): - Live vaccines: contraindicated during therapy. - Immunosuppressive chemotherapy: may increase infection risk. - Antiviral biologics (e.g., interferon): potential additive immunosuppression.

Moderate Interactions (Monitor Closely): - CYP450 substrates: cytokine modulation may alter metabolism. - Anticoagulants: monitor INR or clotting parameters. - Other IL‑1 inhibitors: avoid concurrent use to prevent overlapping immunosuppression.